Researchers at Wayne State University have received a $684,000 research grant from the Department of Defense to explore the genetic and epigenetic factors — factors that interact with genes — that might contribute to this racial and ethnic disparity in prostate cancer risk and progression.
Have you ever dreamed about becoming a Michigan football player? You’ll soon have the chance to turn that dream into reality during the “Michigan Men’s Football Experience,” and it’s all for a charitable cause.
A new clinical trial is testing whether targeting treatments to a genetic anomaly can lead to better treatments for prostate cancer. The trial, led by investigators at the University of Michigan Comprehensive Cancer Center, is being conducted at 11 sites throughout the country.
Ulka Vaishampayan, M.D., leader of the Genitourinary Oncology Multidisciplinary Team at the Barbara Ann Karmanos Cancer Center, has contributed to an article just published in The New England Journal of Medicine comparing two different therapeutic methods in the treatment of metastatic, hormone-sensitive prostate cancer that becomes unresponsive to traditional methods of therapy.
Taking a break from hormone-blocking prostate cancer treatments once the cancer seems to be stabilized is not equivalent to continuing therapy, a new large-scale international study finds.
A new study by researchers from the University of Michigan, Yale School of Public Health, Brown University and Ann Arbor-based Compendia Bioscience provided a comprehensive genomic profiling of patients with pre-treated lethal metastatic prostate cancer, providing insights into mechanisms of resistance.
Prostate cancer is the most frequent and second deadliest cancer men face. A team of Wayne State University researchers recently received $363,660 from the National Cancer Institute of the National Institutes of Health for a project that aims to learn more about the deadly spread of prostate cancer into the bones.
After a 20-year quest to find a genetic driver for prostate cancer that strikes men at younger ages and runs in families, researchers have identified a rare, inherited mutation linked to a significantly higher risk of the disease.
It sure is … something. 97.1 The Ticket’s Jeff Riger is growing a stache for a cause.
Can diet alter disease progression in men with prostate cancer?